MyShare
USLSEAU KLSEHKSG
user
Profile login
Help Center Ask Forum Keyboard Shortcuts

home

ADXS.US | summary | financial summary | prediction chart | global stock news | news graph | volatility | components |pairs | earnings | dividends | sales | compare

Assets: cash current-assets inventory receivables investments invested ppe nta assets net-debt working-capital liabilities long-term-debt accounts-payable non-current-liabilities

Income sheet sales operations-income gross-profit | expenses marketing r-and-d income-before-tax tax income net-income interest-income ebit leases interest earnings

Key Financials ADXS

Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia. Ayala Pharmaceuticals, Inc. is based in Wilmington, Delaware.
symbollastchange%chngnamemcapsectorwiki
ADXS Ayala Pharmaceuticals Inc. 0.027B Healthcare wiki y

symbolprev.closerangecharttargetpercentperiodmonthsduerating
 D  ADXS 0.56 0,-2.179,-2.079,-0.242,-2.179 0.60,0.59,0.55,1.05,0.72,0.87,0.88,0.78,0.69,0.60,0.67,0.62,0.64,0.60,0.55 0.53-0.91 29.73% 267,177,267 3.0 Nov 3-Jul 27 39.57%

1 ADXS US

The following extracted figures are selected by the AI as the most essential for predicting future price movements. The impact shows the impact of the figure on the share price forecast. Sometimes the impact of an increasing beneficial figure may still be downwards when the increase was smaller than expected. The over figure shows if the actual result was higher or lower than the AI would forecast.

Income statement

. Predection Oct 31,23 Jul 31,23 Apr 30,23 Jan 31,23 Oct 31,22
totalRevenue 0.0 0M 0M 0M 0M 0M
grossProfit -0.0 -7M -8M 0M 0M
operatingIncome -6.0 -7M -8M -12M -5M -5M
. netInterestIncome -2.0 -16M -0M -0M 0M 0M
incomeBeforeTax -6.0 -7M -9M -12M -5M -5M
taxProvision 0.0 0M 0M 0M -4M 0M
netIncome -6.0 -7M -9M -7M -5M -5M
otherOperatingExpenses 7.0 7M 8M 12M 5M
netIncomeApplicableToCommonShares
reconciledDepreciation 0.0 0M 0M 0M 0M

Balance sheet

. Predection Oct 31,23 Jul 31,23 Apr 30,23 Jan 31,23 Oct 31,22
. itotalAssets 7.0 7M 12M 21M 26M 26M
totalCurrentAssets 5.0 5M 10M 18M 26M 26M
. cashAndShortTermInvestments 2.0 2M 7M 17M 25M
. cash 2.0 2M 7M 17M 25M 25M
otherAssets
netWorkingCapital -1.0 -17M -4M 1M 8M 23M
netInvestedCapital -1.0 -16M -4M 1M 10M 24M
netDebt 0.0 1M -6M -15M -25M

Cash Flow

. Predection Oct 31,23 Jul 31,23 Apr 30,23 Jan 31,23 Oct 31,22
. totalCashFromOperatingActivities -5.0 -7M -7M -7M -3M -3M
. . depreciationAndAmortization 0.0 0M 0M -0M
. . . changeToAccountReceivables 0.0 0M 0M 0M 0M
. . freeCashFlow -6.0 -7M -7M -7M -3M -3M
. incomeTaxExpense. . 0.0 0M 0M -4M 0M

``` ```